Artificial tears

A technology of liquid and liquid lipids, applied in the direction of drug combination, non-active ingredients of oil/fat/wax, microcapsules, etc., which can solve the problems of additive toxicity, vision, blurring, etc.

Pending Publication Date: 2021-12-10
WATERFORD INSTITUTE OF TECHNOLOGY
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In particular, suspension-based formulations have been reported to show disadvantages such as additive toxicity and blurred vision

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Artificial tears
  • Artificial tears
  • Artificial tears

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Example 1 - Size Measurement and Zeta Potential Measurement:

[0049] Chain diameter and Zeta potential NLC via DLS. Characterization indicates that the cholesterol-castor oil nanostructure lipid carrier (CHCACO-NLC) ratio is 1: 1 sample is most stable. The size and zeta potential of CHCAO-NLC are shown in Table 1. Sample particle size (nm) Zeta potential (MV)

[0050] Table 1. The size and zeta potential of thechcao-NLC.

[0051] sample name Particle size (nm) Zeta Potential (MV) CHCAO1: 1 304 -8.5

Embodiment 2

[0052] Example 2 - Cytotoxicity for prepared chcaco-NLC:

[0053] CHCAO-NLC cytotoxicity was carried out on Human Corneal Epithelium Cells, Hcec. Cells of 10,000 cells / well were inoculated in a 96-well plate, and then cultured for 24 hours in DMEM medium containing 10% FBS. The cells were treated with different concentrations of CHCAO-NLC and cultured with CHCAO-NLC treated with CHCAO-NLC in a moisture of 5% CO2 at 37 ° C for 4 hours. After 4 hours, the medium was replaced with fresh medium, and the cells were maintained for more than 20 hours. After the specified time, MTT (3- (4,5-dimethylthiazole-2-yl) -2,5-diphenyl bromide) reagent was added to each well, and the cells were cultured for 4 hours. The medium in each well was replaced with 200 μl of DMSO to dissolve the crystallization. Record the absorbance (O.D.) with the enzyme label instrument. Calculate the cell viability by using the following equation:

[0054] Cell viability (%) = [o.d. (test) / o.d. (Control)] x100

[0...

Embodiment 3

[0057] Example 3 - Cell Patient Research

[0058] The use of fluorescence microscopy further examines CHCAO-NLC in vitro catalytes in vitro. 5 × 10 per dish 4 The density of a cell is inoculated in a cop-focused impeva. The chcaO-NLC-6 labeled CHCAO-NLC was prepared and exposed to the HCT cells in the medium. After 4 hours at 37 ° C, the medium treatment treated with CHCAO-NLC was removed and the cells were washed. Further cellular intake of cells under fluorescence microscope. The data shows that NLC is internalized in cells, and the coumarin-6 encapsulated in CHCAO-NLC is successfully released into the cytoplasm of HCT cells. Detecting dexamethasone in CHCAO-NLC will be released within HCEC cells ( figure 2 .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a Nanostructured Lipid Carrier (NLC) particle comprising: (i) a solid outer shell comprising a solid lipid, wherein the solid lipid comprises cholesterol; and (ii) a liquid core comprising a liquid lipid, wherein the liquid lipid comprises triglyceride; and related compositions, eye drop dispensers, uses and methods of treatment or prevention of a dry eye disorder in a subject.

Description

Technical field [0001] The present invention relates to a nanostructured lipidcarrier, NLC granules, and associated compositions, uses and treatments. Background technique [0002] Dry eye (dry corneal conjunctivitis) is a common disease with a variety of potential reasons. It is characterized by a long-term lack of lubrication and moisture on the surface of the eye, causing tear film to rupture. The three main components of the tear film are: oil, water and mucin, each component is provided by a different gland, or around the eye. The imbalance between these three components, for example due to functional disorders in one or more gland, resulting in insufficient symptoms of tear film and dry eye. [0003] One of the main reasons for dry eye is the meibomian Gland Dysfunction (MGD). The tippe gland is found in the upper and lower eyelids, which is functionally secreted to the surface of the eye, thereby reducing the evaporation rate of the tear. Dysmal disorder, by blocking or ot...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/51A61K47/28A61K47/44A61P27/04
CPCA61K9/0048A61K47/28A61K47/44A61K9/5123A61P27/04B82Y5/00
Inventor L·菲茨亨利S·库马里
Owner WATERFORD INSTITUTE OF TECHNOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap